The irreversible suppression of HER1/HER2/HER4 is the hallmark of the TKI neratinib, which was created in the United States by Puma Biotechnology, Inc. According to research, individuals with HER2+ breast cancer who have had adjuvant therapy with trastuzumab have a significantly higher two-year invasive disease-free survival rate [92]. Here, ERBB2 is linked to breast carcinoma.